Roupret M, Bertaut A, Pignot G, Neuzillet Y, et al. ALBAN (GETUG-AFU 37): A phase 3, randomized, open-label, international trial of intravenous atezolizumab and intravesical Bacillus Calmette-Guerin (BCG) versus BCG alone in BCG-naive high-risk, non-muscle invasive bladder cancer (NMIBC). Ann Oncol 2025 Dec 31:S0923-7534(25)04787-8. doi: 10.1016/j.annonc.2025.
PMID: 41110692